Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer

INTRODUCTION: Approximately 15%~30% of breast cancers have gene amplification or overexpression of the human epidermal growth factor receptor 2 (HER2), resulting in the chemotherapy resistance, a more-aggressive phenotype and poor prognosis. METHODS: We propose a strategy of nanocarriers co-loaded w...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Wei-Jie, Lin, Shyr-Yi, Chuang, Kuo-Hsiang, Chen, Michael, Ho, Hsiu-O, Chen, Ling-Chun, Hsieh, Chien-Ming, Sheu, Ming-Thau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677924/
https://www.ncbi.nlm.nih.gov/pubmed/36419719
http://dx.doi.org/10.2147/IJN.S388066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677924/
https://www.ncbi.nlm.nih.gov/pubmed/36419719
http://dx.doi.org/10.2147/IJN.S388066

Ejemplares similares